Merrimack Pharmaceuticals Closure: Impact on Shareholders
Merrimack Pharmaceuticals is set to dissolve after receiving a $225 million payment for FDA approval. Shareholders will receive a dividend ...
- Latest
- Trending
Merrimack Pharmaceuticals is set to dissolve after receiving a $225 million payment for FDA approval. Shareholders will receive a dividend ...
Protagenic Therapeutics achieves milestone in Phase I trial for PT00114, a compound for treating stress-related neuro-psychiatric disorders. No adverse reactions ...
Sosei Group Corporation announces operational activities and consolidated results, including significant investment, marketing approval, and partnerships. Despite revenue decrease, the ...
Otsuka's phase 3 trial for AVP-786 in treating agitation in Alzheimer's patients has failed to meet the primary efficacy endpoint. ...
Vertex Pharmaceuticals is capturing the attention of investors with its expansion into pain management and cell/gene therapies. With positive earnings ...
AN2 Therapeutics' stock rating was downgraded by Oppenheimer after pausing its Phase 3 trial. The company is reassessing and discussing ...
NRx Pharmaceuticals receives a $5 million milestone payment for the development of its drug candidate NRX-101, supporting its progress through ...
Anixa Biosciences advances Phase 1 clinical trial for ovarian cancer therapy, increasing dosage and showing promising results. Market responds positively ...
Kintara Therapeutics has launched a clinical trial for REM-001, a promising treatment for cutaneous metastatic breast cancer. The trial aims ...
Cidara Therapeutics receives $11.1 million milestone payment from Mundipharma for European approval of new antifungal drug, Rezzayo. Analysts see potential ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.